Cancer Institute and Hospital, Chinese Academy of Medical Sciences: all 387 studies

Page 2 of 4. Open to participants first (275), then studies with results posted, then the rest; newest registration first within each.

• A Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomicsEnrolling by invitationNCT07107815
• A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination RegimenNot yet recruitingNCT07099794Phase 2
• Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical CancerNot yet recruitingNCT07088731Phase 2
• Hypofractionated vs Conventional RT After Prosthetic Breast ReconstructionRecruitingNCT07084519Phase 3
• the Efficacy of MR-guided Online Adaptive Radiotherapy for Locally Advanced Rectal CancerNot yet recruitingNCT07080411Not applicable
• A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic CholangiocarcinomaRecruitingNCT07063888Phase 2
• Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung CancerRecruitingNCT07057102
• A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene MutationsNot yet recruitingNCT07048964
• Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer PatientsRecruitingNCT07043894Phase 2
• Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal CancerRecruitingNCT07040098Phase 2
• Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric CancerRecruitingNCT07034742Early Phase 1
• Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With ApatinibRecruitingNCT07033819Phase 2
• Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver MetastasesRecruitingNCT07027605
• A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung CancerRecruitingNCT07026669
• Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast CancerNot yet recruitingNCT07019337Phase 2
• Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-ImmunotherapyRecruitingNCT07014202Phase 2
• Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast CancerRecruitingNCT06993506
• Zanubrutinib Combined With G-CVP in Previously Untreated FLRecruitingNCT06959732Phase 2
• The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical StudyRecruitingNCT06958627Phase 2/3
• Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.RecruitingNCT06928922Early Phase 1
• Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid TumorsRecruitingNCT06926751Phase 2
• Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）Enrolling by invitationNCT06910072Phase 2/3
• Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast CancerRecruitingNCT06908668Phase 2
• Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal CancerRecruitingNCT06904677
• Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLCRecruitingNCT06897046Phase 2
• Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant TherapyNot yet recruitingNCT06889402
• A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for ECEnrolling by invitationNCT06863831Not applicable
• Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal CancerNot yet recruitingNCT06858969Phase 2
• Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal CancerNot yet recruitingNCT06858956
• Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver MetastasesRecruitingNCT06848842Phase 2
• PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast CancerNot yet recruitingNCT06842472Phase 2
• Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain MetastasisRecruitingNCT06839560Phase 2
• A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.RecruitingNCT06839547
• Jianzhong Qushi in Chronic RRINot yet recruitingNCT06837597Phase 3
• Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002Not yet recruitingNCT06834438Not applicable
• Familial Breast Cancer in ChinaNot yet recruitingNCT06833216
• Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJRecruitingNCT06808971Phase 2
• Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT06793813Phase 2
• A Study Comparing the Differences Between Young and Non-young Breast CancerEnrolling by invitationNCT06793306
• A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast CancerEnrolling by invitationNCT06791161
• Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic CancerRecruitingNCT06789679Phase 2
• A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast CancerRecruitingNCT06776861
• Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.RecruitingNCT06771609Phase 2
• Hypofractionated Radiotherapy for HNSCC in Elderly PatientsEnrolling by invitationNCT06768125Not applicable
• Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJRecruitingNCT06761846Phase 2
• A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young AdultsRecruitingNCT06761417Phase 2
• Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast CancerRecruitingNCT06757621Phase 3
• Quantitative Neurofeedback Techniques for Treating Perioperative Cognitive Disorders in Elderly PatientsNot yet recruitingNCT06752148Not applicable
• QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDACNot yet recruitingNCT06750861Phase 2
• Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and ChemotherapyNot yet recruitingNCT06691594Phase 2
• Sodium Glycididazole Reduces the Adverse Reactions of Concurrent ChemoradiotherapyRecruitingNCT06667622Phase 2
• Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant TherapyRecruitingNCT06649565
• Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction AdenocarcinomaRecruitingNCT06644352Not applicable
• Super-Hypofractionated Partial Breast IrradiationRecruitingNCT06615466Not applicable
• Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical TrialsRecruitingNCT06612632Phase 1/2
• A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell CarcinomaNot yet recruitingNCT06585878Not applicable
• Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC PatientsNot yet recruitingNCT06577961Phase 1/2
• Phase II Study of FCN-159 in NF2 Nerve Sheath TumorsRecruitingNCT06553365Phase 2
• A Study for Dynamic Prediction Model of Breast Cancer Bone MetastasesNot yet recruitingNCT06544668
• ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal CancerRecruitingNCT06543836Phase 2
• Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMRecruitingNCT06543069Phase 2
• A Study of ES014 in Subjects With Advanced Solid TumorsRecruitingNCT06543056Phase 2
• Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine TumorRecruitingNCT06540937Phase 2
• Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaEnrolling by invitationNCT06540508
• Goal-directed Enteral Nutritional Perioperative ManagementRecruitingNCT06510543Not applicable
• NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid TumorsRecruitingNCT06509490Not applicable
• Longitudinal Study on the Evolution Trend and Influencing Factors of Postoperative Reflux of Esophageal Cancer Based on PEPTEST TechniqueEnrolling by invitationNCT06509022
• Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaRecruitingNCT06509009Phase 2
• MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal CancerRecruitingNCT06498752Phase 2
• GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal CarcinomaNot yet recruitingNCT06490341Phase 2
• Trilaciclib Prevents Myelosuppression With ChemoradiotherapyRecruitingNCT06490081Phase 2
• Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to ImmunotherapyRecruitingNCT06490068Phase 2
• Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the SurgeryRecruitingNCT06483698
• Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain MetastasesNot yet recruitingNCT06483672Phase 2
• SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLCRecruitingNCT06457906Phase 3
• Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.Not yet recruitingNCT06452433Phase 2
• Quantitative Nodal Burden as a Determinant Identifying Ampullary Adenocarcinoma Patients Benefiting From Adjuvant ChemotherapyRecruitingNCT06435767
• Neoadjuvant Comprehensive Treatment for Unresectable Esophageal CancerRecruitingNCT06430658Phase 2
• Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer PatientsRecruitingNCT06429839Phase 2
• Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal CancerRecruitingNCT06421376Phase 2
• Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ AdenocarcinomaRecruitingNCT06417892
• Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural MesotheliomaNot yet recruitingNCT06416930Phase 2
• Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial CancerRecruitingNCT06413992Phase 2
• SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast CancerRecruitingNCT06411457Phase 2
• Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT06410651Phase 2
• Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver CancerNot yet recruitingNCT06408623Phase 2
• NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDACRecruitingNCT06405490Phase 2
• Intensive Adjuvant Therapy for TNBC with BRCA Gene MutationEnrolling by invitationNCT06405295
• Effect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer PatientsEnrolling by invitationNCT06405269
• Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain MetastasesRecruitingNCT06405256
• Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal CancerRecruitingNCT06405139Phase 2
• Clinical Trial of BT02 in Patients With Advanced Solid TumorsRecruitingNCT06404905Phase 1
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor ThrombosisRecruitingNCT06389422Phase 2
• Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGCRecruitingNCT06371586Phase 2
• Transhiatal Tunnel Valvuloplasty for Reconstruction Following the Laparoscopic Proximal GastrectomyRecruitingNCT06354036Not applicable
• Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based StudyRecruitingNCT06350370Not applicable
• Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid TumorsRecruitingNCT06346041Early Phase 1
• NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory StudyRecruitingNCT06345300Phase 2
• Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCCRecruitingNCT06345287Phase 2
• Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell CarcinomaRecruitingNCT06342167Phase 2

← Cancer Institute and Hospital, Chinese Academy of Medical Sciences overview and focus areas